Dr. Reddy’s announces the Launch of Rivastigmine Tartrate Capsules

Hyderabad, India, September 22, 2011:

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Rivastigmine Tartrate Capsules (1.5 mg, 3 mg, 4.5 mg and 6 mg), a bioequivalent generic version of EXELON^®* Capsules in the US market on September 15, 2011 following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy’s ANDA for Rivastigmine tartrate capsules.

The EXELON^®* brand and generic Rivastigmine tartrate had U.S. sales of approximately $92.6 million for the most recent twelve months ending June 2011 according to IMS Health.

Dr. Reddy’s Rivastigmine tartrate capsules 1.5 mg, 3 mg, 4.5 mg and 6 mg strengths are available in 60 count bottles.

Disclaimer
This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy’s
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to: www.drreddys.com

*EXELON is a registered trademark of Novartis Pharmaceuticals Corporation
IMS National Sales Perspectives: Retail and Non-Retail MAT JUNE 2011

For more information please contact:

Investors and Financial Analysts:
Kedar Upadhye at kedaru@drreddys.com / +91-40-66834297
Raghavender R at raghavenderr@drreddys.com / +91-40-49002135
Milan Kalawadia (USA) at mkalawadia@drreddys.com / +1 908-203-4931

Media:
S Rajan at rajans@drreddys.com / +91-40- 49002445